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Introduction
Glaziovianin A (1), isolated from the leaves of the Brazilian tree Ateleia glazioviana, exhibited a broad spectrum of cytotoxicity against a panel of 39 human cancer cell lines (termed JFCR39) at the Japanese Foundation for Cancer Research ( Figure  1) . 1 On the basis of COMPARE analysis, the pattern of the differential cytotoxicities of glaziovianin A (1) suggested that glaziovianin A (1) inhibits cancer cell proliferation by inhibiting tubulin polymerization. 2 Indeed, we previously reported that glaziovianin A (1) arrested the cell cycle progression in M phase as do tubulin inhibitors. 1 Interestingly, glaziovianin A (1) induced abnormal spindle structures with unaligned chromosomes in mitotic cells, but did not influence on the microtubule network in interphase cells. Although the target molecule(s) or inhibitory mechanism remained to be revealed, these results suggest that glaziovianin A (1) is a novel mitotic inhibitor. Mitotic inhibitors including tubulin polymerization inhibitors have become clinically important drugs, especially against breast cancer.
3 Also, glaziovianin A (1) showed antitumor activities in a mouse xenograft model (unpublished data). These results encouraged us to develop novel anticancer drugs based on glaziovianin A (1). A structure-cytotoxicity relationship study of glaziovianin A (1) was preliminarily reported by our group. 4 In the present paper, we describe in detail the structure-activity relationships of glaziovianin A, specifically concerning its cytotoxicity and its effects on cell cycle progression and spindle structure. We also describe the synthesis of molecular probes of glaziovianin A for biological studies and target identification. We previously synthesized glaziovianin A (1) by using Suzuki-Miyaura coupling as a key step (Scheme 1). 5 We used a similar strategy to synthesize glaziovianin A analogues. To develop these analogues, the structure of glaziovianin A (1) can be divided into two structural moieties: an A-ring and a B-ring ( Figure 2 ). Therefore, we synthesized 3-iodochromone analogues as an A-ring and boron compounds as a B-ring. 
Results and discussion

Synthesis of B-ring analogues of glaziovianin A
First, we prepared B-ring analogues of glaziovianin A (Scheme 2). The diol group in 3,6-dimethoxybenzene-1,2-diol (6) 6 was protected as an acetonide group to give compound 7. The bromination of 7 gave a monobromo compound, which was converted into arylboronate 8 by using PdCl 2 (dppf), bis(pinacolato)diboron, and KOAc in DMF at 150 °C. 7 The Suzuki-Miyaura coupling 8 between 3-iodo-6,7-dimethoxy-4H-chromen-4-one (3) 5 and boron compounds, such as arylboronate 8, 2,3,4,5-tetramethoxyphenylboronic acid (10), 9 or commercially available 3,4-(methylenedioxy)phenylboronic acid (11) , gave glaziovianin A analogues 12-14, respectively. On the other hand, bromide 15 was synthesized from selective bromination at the C6' position of glaziovianin A (1). 3 , THF, rt; (e) 3, PdCl 2 (dppf), 1 M Na 2 CO 3 aq., 1,4-dioxane, rt {64% for 12, 11% for 13 (from 9), 41% for 14}; (f) NBS, DMF, rt, 31%.
Synthesis of A-ring analogues of glaziovianin A
Next, we tried to modify the A-ring part of glaziovianin A (Scheme 3). The hydroxy group at the C7 position of 16 10 was protected as a THP group to afford compound 17. Condensation of 17 with N,N-dimethylformamide dimethyl acetal gave an enamine in quantitative yield. Iodinative cyclization of the enamine afforded iodochromone 18. 11 The cross coupling reaction of arylboronate 55 and iodochromone compounds 18 and 19 12 , gave glaziovianin A analogues 20 and 21, respectively. Table 1 summarizes the cytotoxicity of glaziovianin A (1) and  its analogues against HeLa S 3 cells and their calculated Log P  (cLog P) values. 14 Compound 12, which has an acetonide group instead of the methylene acetal group of glaziovianin A (1), showed no cytotoxicity even at 100 M. Also, compound 13, which has methoxy groups at C3' and C4' instead of the methylene acetal group, was much less cytotoxic than glaziovianin A (1). These results indicated that the steric hindrance of C3' and C4' at the B-ring part reduced the cytotoxicity of glaziovianin A (1) to a large extent. Compound 14, which lacks methoxy groups at C2' and C5', was about 100-fold less cytotoxic than glaziovianin A (1). Also, compound 15, which has a bromo group at C6' of the B-ring, was less cytotoxic than glaziovianin A (1). These results suggested that the electron density and/or steric hindrance of the B-ring might be responsible for cytotoxicity. On the other hand, compound 21, which has an extra methoxy group at C5 of the A-ring, showed no cytotoxicity even at 100 M, indicating that the steric hindrance and electron density of the A-ring extinguished cytotoxicity. O 7 -Demethyl analogue 22 exhibited no cytotoxicity, perhaps because of its instability. On the other hand, compounds 24, 25, and 27, which have O 7 -hydrophilic functional groups, showed no cytotoxicity at 100 M, and the cLog P values of these compounds, 1.00, 0.08, and 1.13, are much smaller than that of glaziovianin A (1). These results showed that the improvement of water solubility diminishes cytotoxicity. We previously reported that glaziovianin A (1) inhibited the cell cycle progression in the M-phase with abnormal spindle structures. 1 Here, we investigated the effects of the cytotoxic O 7 -alkylated analogues 26, 28, and 29 on both cell cycle progression and spindle structures. 16, 17 As shown in Figures 3A-E , all the analogues inhibited the cell cycle progression in the G2/M phase at a concentration of 1 μM for 24 h treatment. To confirm whether or not these compounds also induce abnormal spindle structures with unaligned chromosomes, as does 1, microtubules and chromosomes in mitotic cells treated with 1 μM O 7 -alkylated analogues for 6 h were observed ( Figures 3F-J) . Normal bipolar spindles were observed in DMSO-treated cells, but abnormal multipolar spindles were formed in most of the cells treated with 1 ( Figures 3F and 3G, respectively) . As expected, analogues 26, 28, and 29 also induced abnormal multipolar spindles, and these structures were resembled with the spindles induced by 1 ( Figures 3H-J 
Cytotoxicity of glaziovianin A (1) and its analogues against HeLa S 3 cells
Conclusion
In conclusion, we have investigated the structure-cytotoxicity relationships of glaziovianin A (1). The results revealed that O 7 -modified glaziovianin A analogues have strong cytotoxicity against HeLa S 3 cells. Among them, O 7 -benzyl and O 7 -propargyl analogues 28 and 29 completely arrested cell cycle progression, indicating that these compounds are more potent cell cycle inhibitors than glaziovianin A (1). Furthermore, we have synthesized O 7 -modified molecular probes of glaziovianin A for biological studies. Further searches for target biomolecules of glaziovianin A (1) by using these probes are in progress.
Experimental section
Chemistry
General method 1 H NMR spectra were recorded on a JEOL JNM-EX270 (270 MHz) or a Bruker AVANCE 500 (500 MHz) spectrometer. Chemical shifts for 1 H NMR are reported in parts per million (ppm) downfield from tetramethylsilane as the internal standard, and coupling constants are in hertz (Hz) . The following abbreviations are used for spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad. 13 C NMR spectra were recorded on a JEOL JNM-EX270 (67.8 MHz) or a Bruker AVANCE 500 (125 MHz) spectrometer. Chemical shifts for 13 C NMR are reported in ppm, relative to the central line of a triplet at 77.0 ppm for deuteriochloroform. IR spectra were recorded on a JASCO FT/IR-300 instrument and are reported in wavenumbers (cm −1 ). High resolution ESI mass spectra were recorded on an Applied Biosystems QStar/Pulsar i spectrometer. Fuji Silysia silica gel BW-820MH was used for column chromatography. Anhydrous benzene, CH 2 Cl 2 , MeOH, THF, toluene, and MeCN were used as obtained from commercial supplies for moisture-sensitive reaction. Other organic solvents for moisture-sensitive reactions were distilled by standard procedure. MS3A was heated in a microwave oven for 2 minutes.
4,7-Dimethoxy-2,2-dimethylbenzo[d][1,3]dioxole (7)
To a stirred solution of catechol 6 (54.3 mg, 319 mol) in benzene (2.5 mL) were added PPTS (5.5 mg, 21.9 mol) and 2-methoxypropene (0.10 mL, 1.04 mmol) at room temperature. After being stirred at reflux for 48 h, the mixture was cooled to room temperature, diluted with EtOAc (5 mL), and washed with 1 M aqueous NaOH (3 mL). The EtOAc solution was washed with brine (3 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (0. 
5-Bromo-4,7-dimethoxy-2,2-dimethylbenzo[d][1,3]dioxole (7a)
To a stirred solution of acetonide 7 (48.6 mg, 231 mol) in DMF (2.6 mL) was added NBS (34.9 mg, 196 mol) at 0 °C. After being stirred at room temperature for 18 h in dark, the mixture was diluted with water (3 mL) and extracted with CH 2 Cl 2 (2 mL×3). The combined extracts were washed with brine (5 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (2.0 g, hexane-CH 2 
2-(4,7-Dimethoxy-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8)
To a stirred solution of bis(pinacolato)diboron (52.5 mg, 207 mol), PdCl 2 (dppf)·CH 2 Cl 2 (11.3 mg, 13.8 mol), and KOAc (54.5 mg, 556 mol) in DMF (0.60 mL) was added a solution of bromide 7a (39.7 mg, 138 mol) in DMF (0.50 mL) at room temperature. After being stirred at 150 °C under a stream of N 2 for 3 h, the mixture was cooled to room temperature, diluted with EtOAc (4 mL), and washed with brine (2 mL). The EtOAc solution was dried (Na 2 SO 4 ), filtered through a pad of Florisil, and concentrated. The residual oil was purified by column chromatography on silica gel (0.8 g, hexane-EtOAc = 100:1 
3-(4,7-Dimethoxy-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-4H-chromen-4-one (12)
All solvents were degassed by freeze-thawing. To a stirred solution of arylboronate 8 (12.9 mg, 38.4 mol) and PdCl 2 (dppf)·CH 2 Cl 2 (3.1 mg, 3.79 mol) in 1,4-dioxane (0.25 mL) were added aqueous 1 M Na 2 CO 3 (0.19 mL, 190 mol) and iodochromone 3 (19.1 mg, 57.5 mol) in 1,4-dioxane (0.30 mL) at room temperature. After being stirred at room temperature under a stream of N 2 for 36 h, the mixture was diluted with EtOAc (2 mL) and filtered through a pad of Florisil. The filtrate was washed with brine (4 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane-EtOAc = 10:1 → 1:1) to give a brown solid (containing Pd-metal) (10.1 mg, 64%). The brown solid (10.1 mg) was dissolved in CHCl 3 (1 mL), and SiliaBond (SILICYCLE, SiliaBond Thiourea, 100 mg) was added. The resulting mixture was stirred at room temperature for 30 min, filtered, and concentrated to give glaziovianin A analogue 12 ( 
2,3,4,5-Tetramethoxyphenylboronic acid (10)
To a stirred solution of tetramethoxybenzene 9 (101 mg, 510 mol) in THF (1.0 mL) was added n-BuLi (1.63 M solution in hexane, 0.34 mL, 554 mol) slowly at room temperature. After the mixture was stirred at room temperature for 15 min, B(OMe) 3 (0.34 mL, 2.99 mmol) was added into the mixture at -78 °C. The reaction mixture was stirred at room temperature for 3 h, diluted with aqueous 1 M HCl (2.5 mL), stirred at room temperature for 3 h, and extracted with ether (2 mL×3). The combined extracts were washed with brine (5 mL) and dried (MgSO 4 ). Removal of the solvent afforded boronic acid 10 (138 mg) as a white solid, which was used for the next reaction without further purification.
6,7-Dimethoxy-3-(2,3,4,5-tetramethoxyphenyl)-4H-chromen-4-one (13)
To a stirred solution of crude boronic acid 10 (41.0 mg, 152 mol) and PdCl 2 (dppf)·CH 2 Cl 2 (17.8 mg, 15.4 mol) in 1,4-dioxane (1.0 mL) were added 1 M Na 2 CO 3 aq. (0.75 mL, 750 mol) and iodochromone 3 (103 mg, 310 mol) in 1,4-dioxane (1.0 mL) at room temperature. After being stirred at room temperature under a stream of N 2 for 17 h, the reaction mixture was diluted with water (1 mL) and extracted with CH 2 Cl 2 (2 mL×3). The combined extracts were washed with brine (3 mL), dried (Na 2 SO 4 ), filtered through a pad of Florisil, and concentrated. The residual oil was purified by column chromatography on silica gel (3.0 g, hexane-EtOAc = 4:1 → 2:1) to give a brown solid (containing Pd-metal) (7.0 mg). The brown solid (7.0 mg) was dissolved in CHCl 3 (1 mL), and SiliaBond (SILICYCLE, SiliaBond Thiourea, 70 mg) was added. The resulting mixture was stirred at room temperature for 30 min, filtered, and concentrated to give glaziovianin A analogue 13 (7 To a stirred solution of boronic acid 11 (50.4 mg, 152 mol) and PdCl 2 (dppf)·CH 2 Cl 2 (17.1 mg, 14.8 mol) in 1,4-dioxane (1.0 mL) were added 1 M Na 2 CO 3 aq. (0.75 mL, 750 mol) and iodochromone 3 (108 mg, 323 mol) in 1,4-dioxane (1.0 mL) at room temperature. After being stirred at room temperature under a stream of N 2 for 12 h, the reaction mixture was diluted with water (1 mL) and extracted with CH 2 Cl 2 (2 mL×3). The combined extracts were washed with brine (3 mL), dried (Na 2 SO 4 ), filtered through a pad of Florisil, and concentrated. The residual oil was purified by column chromatography on silica gel (0.7 g, hexane-CHCl 3 To a stirred solution of glaziovianin A (1) (10.2 mg, 26.4 mol) in DMF (0.25 mL) was added NBS (4.7 mg, 26.6 mol) at room temperature. After being stirred at room temperature for 6 h, the reaction mixture was diluted with water (0.5 mL) and extracted with CH 2 Cl 2 (1 mL×3). The combined extracts were washed with brine (2 mL), dried (Na 2 SO 4 ), and concentrated. The residual oil was purified by column chromatography on silica gel (0.7 g, hexane-EtOAc = 5:1 
1-(2-Hydroxy-5-methoxy-4-(tetrahydro-2H-pyran-2-yloxy)phenyl)ethanone (17)
To a stirred solution of phenol 16 (16.5 mg, 90.7 mol) in CH 2 Cl 2 (0.90 mL) were added DHP (102 L, 1.12 mol) and PPTS (3.2 mg, 12.7 mol) at 0 °C. After being stirred at room temperature for 18 h, the reaction mixture was diluted with saturated aqueous NaHCO 3 (1 mL) and extracted with CH 2 Cl 2 (2 mL×3). The combined extracts were washed with brine (2 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (1.5 g, hexane-EtOAc 
(E)-3-(Dimethylamino)-1-(2-hydroxy-5-methoxy-4-(tetrahydro-2H-pyran-2-yloxy)phenyl)prop-2-en-1-one (17a)
3-Iodo-6-methoxy-7-(tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one (18)
To a stirred solution of enamine 17a (150 mg, 467 mol) in CHCl 3 (4.7 mL) were added pyridine (0.19 mL, 2.36 mmol) and I 2 (250 mg, 984 mol) at 0 °C. After being stirred at room temperature for 12 h in dark, the mixture was diluted with saturated aqueous Na 2 S 2 O 3 (5 mL), stirred at room temperature for 10 min, and extracted with EtOAc (5 mL×3). The combined extracts were washed with brine (10 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (8 g, hexane-EtOAc = 10:1 
3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-7-(tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one (20)
All solvents were degassed by freeze-thawing. To a stirred solution of arylboronate 5 (10.1 mg, 32.8 mol) and PdCl 2 (dppf)·CH 2 Cl 2 (2.2 mg, 2.69 mol) in 1,4-dioxane (0.10 mL) were added aqueous 1 M Na 2 CO 3 (0.13 mL) and iodochromone 18 (10.4 mg, 25.9 mol) in 1,4-dioxane (0.22 mL) at room temperature. After being stirred at room temperature under a stream of N 2 for 24 h, the reaction mixture was diluted with water (1 mL) and extracted with CH 2 Cl 2 (1 mL×3). The combined extracts were washed with brine (2 mL), dried (Na 2 SO 4 ), filtered through a pad of Florisil, and concentrated. The residual oil was purified by column chromatography on silica gel (0.7 g, hexane-EtOAc = 4:1 → 2:1) to give a brown oil (7.9 mg). The brown oil (7.9 mg) was dissolved in CHCl 3 (1 mL), and SiliaBond (SILICYCLE, SiliaBond Thiourea, 80 mg) was added. The resulting mixture was stirred at room temperature for 30 min, filtered, and concentrated to give a glaziovianin A analogue 20 (7.8 136.9, 136.6, 121.3, 118.4, 118.0, 109.9, 105.3, 104.2, 101.9,  97.1, 62.1, 60.2, 56.9, 56.4, 30.1, 25.1 
3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-5,6,7-trimethoxy-4H-chromen-4-one (21)
All solvents were degassed by freeze-thawing. To a stirred solution of arylboronate 5 (20.6 mg, 66.9 mol) and PdCl 2 (dppf)·CH 2 Cl 2 (5.8 mg, 7.10 mol) in 1,4-dioxane (0.45 mL) were added aqueous 1 M Na 2 CO 3 (0.32 mL, 320 mol) and iodochromone 19 (36.5 mg, 101 mol) in 1,4-dioxane (0.48 mL) at room temperature. After being stirred at room temperature under a stream of N 2 for 48 h, the reaction mixture was diluted with EtOAc (2 mL) and filtered through a pad of Florisil. The filtrate was washed with brine (4 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (1.5 g, hexane-EtOAc = 5:1 
3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-7-hydroxy-6-methoxy-4H-chromen-4-one (22)
To a stirred solution of glaziovianin A analogue 20 (24.0 mg, 52.6 mol) in CHCl 3 (0.50 mL) and MeOH (0.10 mL) was added p-TsOH·H 2 O (1.1 mg, 5.79 mol) at room temperature. After the mixture was stirred at room temperature for 3 h, Et 3 N (0.01 mL) was added. Removal of solvent gave a solid, which was purified by column chromatography on silica gel (0.6 g, hexane-EtOAc 
(3R,4S,5R)-2-(Acetoxymethyl)-6-(3-(4,7-dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4H-chromen-7-yloxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (24)
To a stirred solution of O 7 -demethyl analogue 22 (24.7 mg, 66.4 mol) and MS3A (244 mg) in CH 2 Cl 2 (0.50 mL) were added a solution of imidate 23 (65.1 mg, 133 mol) in CH 2 Cl 2 (0.50 mL) and BF 3 ·Et 2 O (0.03 mL, 243 mol) at 0 °C. After being stirred at room temperature for 12 h, the mixture was diluted with water (2 mL) and extracted with CH 2 Cl 2 (2 mL×3). The combined extracts were washed with brine (5 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (0.7 g, hexane-EtOAc = 4:1 → 2:1) to give tetraacetyl glycosylisoflavone 24 (mixture of anomeric isomers, -isomer: 1.9 mg, 4.1%; -isomer: 10.7 mg, 23%) as white solids: 24 (-isomer): IR (CHCl 3 ) 3009, 2940,  1672, 1667, 1646, 1522, 1434, 1245 
3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-7-((3R,4S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one (25)
To a stirred solution of tetraacetyl glycosylisoflavone 24 (mixture of anomeric isomers, 4.5 mg, 6.41 mol) in MeOH (0.09 mL) was added NaOMe (3.5 mg, 69.4 mol) at 0 °C. After being stirred at room temperature for 1 h, the mixture was diluted with water (1 mL) and extracted with CHCl 3 (1 mL×6 
7-(Allyloxy)-3-(4,7-dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4H-chromen-4-one (26)
To a stirred solution of O 7 -demethyl analogue 22 (6.1 mg, 16.4 μmol) in MeCN (0.16 mL) were added K 2 CO 3 (4.5 mg, 32.6 μmol) and allyl bromide (2.1 μL, 23.6 μmol) at room temperature. After being stirred at room temperature for 5 h, the mixture was diluted with saturated aqueous NaHCO 3 (1 mL) and extracted with CH 2 Cl 2 (2 mL×3). The combined extracts were washed with brine (2 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane-EtOAc 
7-(2,3-Dihydroxypropoxy)-3-(4,7-dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4H-chromen-4-one (27)
To a stirred solution of allyl ether 26 (5.0 mg, 12.1 mol) in pyridine (0.12 mL) was added OsO 4 (0.4 M solution in THF, 0.04 mL, 16.0 mol) at room temperature. After being stirred at room temperature for 1.5 h, the reaction mixture was diluted with saturated aqueous NaHSO 3 (1 mL), stirred at room temperature for 1 h, and extracted with CH 2 Cl 2 (1 mL×3). The combined extracts were washed with brine (2 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane-EtOAc = 1:1 → 1:4) to give diol 27 (4.5 mg, 84%) as a white solid: IR (CHCl 3 ) 3508,  2968, 1637, 1608, 1505, 1458 
7-(Benzyloxy)-3-(4,7-dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4H-chromen-4-one (28)
To a stirred solution of O 7 -demethyl analogue 22 (6.8 mg, 18.3 mol) in MeCN (0.18 mL) were added K 2 CO 3 (5.2 mg, 37.7 mol) and benzyl bromide (3.2 L, 26.9 mol). After being stirred at room temperature for 5 h, the mixture was diluted with saturated aqueous NaHCO 3 (1 mL) and extracted with CH 2 Cl 2 (2 mL×3). The combined extracts were washed with brine (2 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane-EtOAc = 5:1 → 3:1) to give benzyl ether 28 (6.8 
3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-7-(prop-2-ynyloxy)-4H-chromen-4-one (29)
To a stirred solution of O 7 -demethyl analogue 22 (6.1 mg, 16.4 mol) in MeCN (0.16 mL) were added K 2 CO 3 (4.5 mg, 32.6 mol) and propargyl bromide (2.1 L, 23.6 mol). After being stirred at room temperature for 5 h, the mixture was diluted with saturated aqueous NaHCO 3 (1 mL) and extracted with CH 2 Cl 2 (2 mL×3). The combined extracts were washed with brine (2 mL), dried (Na 2 SO 4 ), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane-EtOAc = 5:1 → 3:1) to give propargyl ether 29 (4.5 mg, 67%) as a white solid: IR (CHCl 3 ) 3306, 3008, 2934, 1638, 1609, 1502, 1470 
tert-Butyl 6-(6-(benzyloxy)hexanamido)hexylcarbamate (32)
To a stirred solution of 6-benzyloxyhexanoic acid 31 (97.3 mg, 450 mol) in DMF (3.5 mL) were added HOBt (67.3 mg, 499 mol) and DCC (103 mg, 500 mol) at 0 °C. After the mixture was stirred at 0 °C for 15 min, mono-Boc-1,6-diaminohexane 30 (107 mg, 461 mol) was added at 0 °C. After being stirred at room temperature for 12 h, the mixture was filtered and concentrated. The crude product was diluted with EtOAc (10 mL), washed with saturated aqueous NaHCO 3 (5 mL), water (5 mL), saturated aqueous NH 4 Cl (5 mL), and brine (5 mL). The combined extracts were dried (Na 2 SO 4 ) and concentrated. The residual oil was purified by column chromatography on silica gel (3.0 g, CHCl 3 -MeOH = 1:0 
tert-Butyl 6-(6-hydroxyhexanamido)hexylcarbamate (32a)
To a stirred solution of amide 32 (153 mg, 364 mol) in EtOH (4.0 mL) was added 5% Pd/C (50% water wet, 80.0 mg) at room temperature. After being stirred at room temperature for 12 h under H 2 , the mixture was filtered through a pad of Celite and concentrated. The residual solid was purified by column chromatography on silica gel (2. 
tert-Butyl 6-(6-bromohexanamido)hexylcarbamate (33)
To a stirred solution of alcohol 32a (107 mg, 324 mol) in CH 2 Cl 2 (3.2 mL) were added NBS (69.4 mg, 390 mol) and Ph 3 P (102 mg, 389 mol) at room temperature. After being stirred at room temperature for 14 h, the mixture was diluted with water (5 mL) and extracted with CH 2 Cl 2 (5 mL×3). The combined extracts were washed with brine (10 mL), dried (Na 2 SO 4 ), and concentrated. The residual oil was purified by column chromatography on silica gel 29 (m, 10H), 1.43 (s, 9H) ; 13 To a stirred solution of O 7 -demethyl analogue 22 (6.9 mg, 18.5 mol) and bromide 33 (21.1 mg, 53.8 mol) in CH 2 Cl 2 (0.27 mL) was added K 2 CO 3 (7.4 mg, 53.6 mol) at 0 °C. After being stirred at reflux for 18 h, the mixture was diluted with water (1 mL) and extracted with CH 2 Cl 2 (1 mL×3). The combined extracts were washed with brine (1 mL), dried (Na 2 SO 4 ), and concentrated. The residual oil was purified by column chromatography on silica gel (0.6 g, hexane-EtOAc = 1:4) to give coupling compound 33a (4.3 mg, 34%) To a stirred solution of coupling compound 33a (4.3 mg, 6.29 mol) in CH 2 Cl 2 (0.10 mL) was added TFA (0.05 mL, 67.5 mol) at 0 °C. The mixture was stirred at room temperature for 4 h and concentrated. The residual oil was purified by column chromatography on silica gel (0.6 g, CHCl 3 To a stirred solution of amine 34 (2.7 mg, 3.87 mol) and (+)-biotin N-hydroxysuccinimide ester 35 (2.0 mg, 5.87 mol) in DMF (0.08 mL) was added Et 3 N (3.0 L, 21.6 mol) at room temperature. After being stirred at room temperature for 14 h, the mixture was diluted with brine (0.5 mL) and extracted with CH 2 Cl 2 (1 mL×3). The combined extracts were dried (Na 2 SO 4 ) and concentrated. The residual oil was purified by column chromatography on silica gel (0.6 g, CHCl 3 
(E)-Methyl 6-hydroxyhex-4-enoate (38)
To a stirred solution of aldehyde 37 (535 mg, 3.77 mmol) in MeOH (15 mL) was added NaBH 4 (171 mg, 4.52 mmol) at 0 °C. After being stirred at 0 °C for 1 h, the mixture was diluted with saturated aqueous NH 4 Cl (8 mL) and water (30 mL) and extracted with CH 2 Cl 2 (20 mL×3 
(E)-Methyl 6-(tert-butyldimethylsilyloxy)hex-4-enoate (39)
To a stirred solution of allylic alcohol 38 (370 mg, 2.57 mmol) in DMF (26 mL) were added imidazole (385 mg, 5.65 mmol) and TBSCl (427 mg, 2.83 mmol) at room temperature. After being stirred at room temperature for 2 h, the mixture was diluted with water (10 mL) and extracted with EtOAc (15 mL×3). The combined extracts were washed with brine (10 mL), dried (Na 2 SO 4 ), and concentrated. The residual oil was purified by column chromatography on silica gel (17 g, EtOAc-hexane = 30:1 4.1.29. (E)-tert-Butyl 6-(6-(tert-butyldimethylsilyloxy)hex-4-enamido)hexylcarbamate (40) To a stirred solution of TBS compound 39 (314 mg, 1.22 mmol) in toluene (4.1 mL) was added amine 30 (394 mg, 1.82 mmol) at room temperature. After being stirred at reflux for 24 h, the mixture was cooled to room temperature, diluted with water (5 mL), and extracted with CH 2 Cl 2 (5 mL×3). The combined extracts were washed with brine (5 mL), dried (Na 2 SO 4 ), and concentrated. The residual oil was purified by column chromatography on silica gel (18 g 
(E)-tert-Butyl 6-(6-hydroxyhex-4-enamido)hexylcarbamate (41)
To a stirred solution of TBS ether 40 (360 mg, 814 mol) in THF (8.1 mL) was added TBAF (276 mg, 1.06 mmol) at room temperature. After being stirred at room temperature for 4 h, the mixture was diluted with saturated NH 4 Cl (7 mL) and extracted with CH 2 Cl 2 (8 mL×3). The combined extracts were washed with brine (10 mL), dried (Na 2 SO 4 ), and concentrated. The residual oil was purified by column chromatography on silica gel (10 g, 
(E)-tert-Butyl 6-(6-bromohex-4-enamido)hexylcarbamate (42)
To a stirred solution of allylic alcohol 41 (222 mg, 677 mol) in CH 2 Cl 2 (6.8 mL) were added Ph 3 P (213 mg, 813 mol) and NBS (145 mg, 815 mol) at room temperature. After being stirred at room temperature for 13 h, the mixture was diluted with water (5 mL) and extracted with CH 2 Cl 2 (7 mL×3). The combined extracts were washed with brine (10 mL), dried (Na 2 SO 4 ), and concentrated. The residual oil was purified by column chromatography on silica gel (13 g, CHCl 3 -MeOH = 1:0 
